Dostarlimab may cause immune-mediated adverse reactions.
- TRADE NAME: Jemperli (GSK)
- INDICATIONS:
Treatment of advanced endometrial cancer following prior treatment with a platinum-containing drug regimen.
- CLASS: Biologic, Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor), Monoclonal antibody, Programmed death receptor-1 (PD-1) inhibitor
- HALF-LIFE: 25.4 days
- FDA APPROVAL DATE: 4/22/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Based on its mechanism of action, dostarlimab can cause fetal harm when administered in pregnancy. Contraception is advised.
- See adverse reactions attributed to class:
Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
